QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 augmedix-q2-2024-gaap-eps-016-misses-013-estimate-sales-13664m-beat-13636m-estimate

Augmedix (NASDAQ:AUGX) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by...

 lake-street-downgrades-augmedix-to-hold

Lake Street analyst Brooks O'Neil downgrades Augmedix (NASDAQ:AUGX) from Buy to Hold.

 ai-focused-healthcare-documentation-provider-augmedix-goes-private-in-139m-deal

Augmedix to be acquired by Commure, Inc. for $139 million in equity. Augmedix stockholders to receive $2.35 per share. The acqu...

 augmedix-announced-that-emergency-services-a-physician-owned-emergency-medicine-services-group-in-columbus-ohio-is-introducing-augmedix-go-ed-to-physicians-in-the-emergency-department-at-the-second-largest-healthcare-system-in-central-ohio

Augmedix Go ED is a fully automated, generative AI (GenAI) powered medical documentation product for emergency departments (EDs...

 lake-street-maintains-buy-on-augmedix-lowers-price-target-to-35

Lake Street analyst Brooks O'Neil maintains Augmedix (NASDAQ:AUGX) with a Buy and lowers the price target from $8 to $3.5.

 maxim-group-downgrades-augmedix-to-hold

Maxim Group analyst Allen Klee downgrades Augmedix (NASDAQ:AUGX) from Buy to Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION